Navigation Links
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Date:11/1/2007

to fund operations for the next two to three years.

Pipeline Update

GATTEX

Nycomed has confirmed to NPS its commitment to license GATTEX for development and commercialization outside of North America. Under the terms of the agreement announced in September 2007, Nycomed will now pay NPS the $25 million balance of the $35 million up-front payment due NPS for the rights to develop and market GATTEX outside North America. In October 2007, NPS announced top-line results of the Phase 3 study of GATTEX in patients with short bowel syndrome (SBS). The company has requested a meeting to discuss the next steps in the drug's regulatory approval process with the FDA this year. NPS believes GATTEX could generate U.S. sales of between $150 and $250 million in this indication.

NPS is also running pre-clinical studies of GATTEX in support of a pediatric IND in necrotizing enterocolitis. NEC affects 12,000 neonates annually in the U.S. and mortality approaches 50% in infants weighing less than fifteen-hundred grams. Additional preclinical studies in chemotherapy-induced gastrointestinal mucositis will be initiated very soon. Chemotherapy-induced GI mucositis affects over 500,000 cancer patients in the U.S. annually.

Cinacalcet

NPS recently announced that Kirin Pharma has received approval to market cinacalcet HCl in Japan. This regulatory event triggered a $2 million milestone payment to NPS.

PREOS

In September 2007, the FDA granted orphan drug status for PREOS as a treatment for hypoparathyroidism. The company is currently supporting a two-year study with PREOS in patients with hypoparathyroidism. The study was initiated by Dr. John Bilezikian at Columbia University and is now 96% enrolled.

The company believes that as a result of recent fundraising activities, sales of non-core assets and the GATTEX partnership with Nycomed, it now has the financial resources to fund the continued U.S. development of PREOS in a variety of ind
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Francisco, California (PRWEB) July 31, 2014 ... systems that inform therapeutic decision-making in oncology, today announced ... August 14, 2014 to discuss the Company's financial results ... provide an update about the business in the current ... audio call beginning on Thursday, August 14, 2014, at ...
(Date:7/31/2014)... 31, 2014 Rancho BioSciences , ... of Omicsoft’s Array Suite with tranSMART . ... able to send data in tranSMART to Array Suite ... versions of tranSMART including the new 1.2 release. ... and storage for the analysis of high dimensional quantification ...
(Date:7/31/2014)... MA (PRWEB) July 31, 2014 ... (UC) and collaboration company, is proud to announce ... (LMS). LMS complements Adobe Connect’s elearning tools to ... LMS delivers content with training tools for desktop ... eLearning with LMS is the perfect online training ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today ... Food and Drug Administration (FDA) rare pediatric disease priority ... (BLA) submission for alirocumab.  The priority review voucher entitles ... which provides for an expedited 6-month review from the ...
Breaking Biology Technology:CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... , SOUTH PLAINFIELD, N.J., Sept. 2 PTC ... its option to collaborate on advancing drug discovery efforts on ... (Gene Expression Modulation by Small-molecules) technology. , , ... , , In September 2007, Celgene made ...
... , SAN DIEGO, Sept. 2 Results from ... developmental product candidates will be presented at the ... held at The Moscone Center in San Francisco on September 12-15, 2009. ... , , , Fidaxomicin ...
... , SOUTH SAN FRANCISCO, Calif., Sept. ... the first commercial sales of a new 20 microgram per ... York Heart Association Class III and IV pulmonary arterial hypertension ... Ventavis in half the volume, which is expected to reduce ...
Cached Biology Technology:PTC Therapeutics Announces Celgene Exercised Option to Drug Discovery Collaboration 2Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 3Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States 2Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States 3
(Date:7/30/2014)... researchers from the University of Helsinki and the Universitat ... in mice morphological changes which have taken millions of ... the embryonic development of mice teeth, induced in the ... similar to those observed in the fossil registry of ... ago. , To modify the development of their ...
(Date:7/30/2014)... University associate professor Andrew S. Mount, performed cutting-edge research ... for novel anti-fouling paint for ships and boats and ... The team,s findings, published in Nature Communications ... that attaches to a wide variety of surfaces using ... an underwater heavy-duty adhesive. , "In previous research, we ...
(Date:7/30/2014)... Limited today announced an across-the-board increase in Impact ... 2013 InCites Journal Citation Reports (Thomson Reuters, 2014) ... Journal , Essays in Biochemistry , ... all received increases in their Impact Factors. ... and published by Portland Press Limited. , 2014 ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2
... Studying thousands of patients, Japanese researchers have found a ... three cancers esophageal, head and neck, and lung. ... of developing these diseases. In the May issue ... the American Association for Cancer Research, scientists from Aichi ...
... A Swiss marine biologist and an Australian quantum physicist have ... Reef, Australia, can see a world invisible to all other ... have shown that mantis shrimp not only have the ability ... but have optimal polarisation vision a first for any ...
... in the February 2008 issue of HortScience offers new ... athletic fields ready for fall sports more quickly. Results ... pare down the usual 9- to 12-month waiting period ... autumn football traffic. Dr. John Stier, Associate Professor ...
Cached Biology News:Tooth loss strongly linked to risk of esophageal, head and neck, and lung cancer 2Shrimps see beyond the rainbow 2Shrimps see beyond the rainbow 3Establishing faster-growing, durable football fields 2
Experion Pro260 chips are the microfluidic chips used to perform protein analysis with the Experion automated electrophoresis system. Each chip has the capacity to run 10 protein samples. Supplied as...
... discovery system miniaturizes, integrates and automates ... LabChip technology, the LabChip 3000 performs ... flow fashion. LabChip assays are separations-based, ... what is achievable in homogenous, well-based ...
... range are part of your production or ... particle size is important to you. You ... the component populations in your sample every ... uses Photon Correlation Spectroscopy (PCS) , which ...
... Fermentation System to achieve high experimental ... maximum information output 4 up ... with small-scale requirements provides users with ... E.coli, Pichia pastoris, yeast, fungi or ...
Biology Products: